None listed
Conditions
Interventions
Drug : Patients with OAB and voidng symptoms were treated with antimuscarinic Vesicare 5 mg (Solifenacin Succinate 5 mg) once daily and with antimuscarinic Vesicare 5 mg (Solifenacin Succinate 5 mg) a
Sponsors
Korea University Ansan Hospital
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Women aged 19 ~79 years 2. OAB patients planned treat with solifenacin 3. OABSS total score = 3,OABSS subscore (Q3)=2 and more than 6 points of Voiding sx subscore (sum of 1,3,5,6 items) on IPSS 4. =3 urgency episodes per 24 h in a 3-day voiding diary 5. Those who have symptoms of overactive bladder symptom for more than 3 months before screening 6. Those who have the ability to write the voiding diary and the questionnaire accurately 7. A person who voluntarily participates in the observation study and agrees in writing to the subject consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with acute cystitis. 2. Patients with undergoing alphablocker or anticholinergics. 3. Patients who do not agree with this study. 4. Pregnant and lactating women. 5. Patient with hypersensitivity of TruPass 8 mg or Vesicare 5 mg. 6. Patients with residual urine >200cc 7. Those with a history of acute urinary retention. 8. Patients with acute myocardiac infarction, angina, arrythemia or cardiac pacemaker 9. Those who underwent surgery that could affect urinary function within 24 hours of screening 10. Severe gastrointestinal disease or myasthenia gravis 11. Patients with narrow angle glaucoma 12. patients who treated with hemodialysis 13. Patients with severe renal impairment (CCr <30 ml / min) who have moderate hepatic impairment and are co-administered with potent CYP3A4 inhibitors (eg, ketoconazole, clarithromycin, itraconazole, ritonavir) 14. Those who participated in other interventional clinical trials within 3 months of screening 15. A person who has or has a history of a malignant tumor. 16. Patients with genetic problems such as galactose intolerance, Lapp lactose dehydrogenase deficiency, glucose-galactose uptake disorder 17. Any other person who is ineligible to participate in the observational study when the examiner or the examiner judges
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change subscore of IPSS (Voiding symptom score, sum 1,3,5,6) | — |
Secondary
| Measure | Time frame |
|---|---|
| Total IPSS score;QoL score on IPSS;Change of OABSS score;Change of Q max in uroflowmetry;safety | — |
Countries
Korea, Republic of
Contacts
Public ContactBum Sik Tae
Korea University Ansan Hospital
Outcome results
None listed